209 results on '"CRISTESCU, R."'
Search Results
2. How microbiomes can help inform conservation: landscape characterisation of gut microbiota helps shed light on additional population structure in a specialist folivore
3. Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma
4. Antimicrobial polycaprolactone/polyethylene glycol embedded lysozyme coatings of Ti implants for osteoblast functional properties in tissue engineering
5. Antimicrobial activity of biopolymeric thin films containing flavonoid natural compounds and silver nanoparticles fabricated by MAPLE: A comparative study
6. Microbial colonization of biopolymeric thin films containing natural compounds and antibiotics fabricated by MAPLE
7. 190MO Association of 18-Gene expression profile (GEP) with clinical outcomes in patients with metastatic triple-negative breast cancer (mTNBC) treated with pembrolizumab (Pembro) or chemotherapy (Chemo) in KEYNOTE-119
8. Pulsed Laser Processing of Functionalized Polysaccharides for Controlled Release Drug Delivery Systems : Functionalized Polysaccharides Processed for Drug Delivery
9. Antimicrobial activity of biopolymer–antibiotic thin films fabricated by advanced pulsed laser methods
10. Functionalized porphyrin conjugate thin films deposited by matrix assisted pulsed laser evaporation
11. North Stradbroke Island: An Island ark for Queensland's koala population?
12. Evaluating the genetic consequences of population subdivision as it unfolds and how to best mitigate them: A rare story about koalas.
13. Magnetic core/shell nanoparticle thin films deposited by MAPLE: Investigation by chemical, morphological and in vitro biological assays
14. MAPLE deposition of Mn(III) metalloporphyrin thin films: Structural, topographical and electrochemical investigations
15. Deposition of antibacterial of poly(1,3-bis-(p-carboxyphenoxy propane)-co-(sebacic anhydride)) 20:80/gentamicin sulfate composite coatings by MAPLE
16. Functional porphyrin thin films deposited by matrix assisted pulsed laser evaporation
17. Functional polyethylene glycol derivatives nanostructured thin films synthesized by matrix-assisted pulsed laser evaporation
18. Thin films of polymer mimics of cross-linking mussel adhesive proteins deposited by matrix assisted pulsed laser evaporation
19. Laser processing of polyethylene glycol derivative and block copolymer thin films
20. Functionalized polyvinyl alcohol derivatives thin films for controlled drug release and targeting systems: MAPLE deposition and morphological, chemical and in vitro characterization
21. Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase 3 trial in patients with gastroesophageal adenocarcinoma
22. Matrix-assisted pulsed laser methods for biofabrication
23. MAPLE applications in studying organic thin films
24. Laser processing of natural mussel adhesive protein thin films
25. Processing of poly(1,3-bis-( p-carboxyphenoxy propane)- co-(sebacic anhydride)) 20:80 (P(CPP:SA)20:80) by matrix-assisted pulsed laser evaporation for drug delivery systems
26. Matrix assisted pulsed laser evaporation of cinnamate-pullulan and tosylate-pullulan polysaccharide derivative thin films for pharmaceutical applications
27. Matrix assisted pulsed laser evaporation of poly( d, l-lactide) thin films for controlled-release drug systems
28. Polycaprolactone biopolymer thin films obtained by matrix assisted pulsed laser evaporation
29. Deposition of biopolymer thin films by matrix assisted pulsed laser evaporation
30. Laser deposition of cryoglobulin blood proteins thin films by matrix assisted pulsed laser evaporation
31. Matrix assisted pulsed laser evaporation processing of triacetate-pullulan polysaccharide thin films for drug delivery systems
32. A Comparison Between Cone Beam-Computed Tomography and Ex Vivo Measurement of the Working Length: OR 58
33. Laser deposition of fibrinogen blood proteins thin films by matrix assisted pulsed laser evaporation
34. Processing of mussel-adhesive protein analog copolymer thin films by matrix-assisted pulsed laser evaporation
35. Processing of mussel adhesive protein analog thin films by matrix assisted pulsed laser evaporation
36. Pulsed laser deposition of biocompatible polymers: a comparative study in case of pullulan
37. New results in pulsed laser deposition of poly-methyl-methacrylate thin films
38. Laser Thin Film Processing of Biopolymers: Mussel Adhesive Protein Analog
39. 1416P Genomic landscape of late-stage gastric cancer
40. 1048P Baseline and post-treatment biomarkers of resistance to anti-PD-1 (aPD1) therapy in acral and mucosal melanoma
41. 796P Association between biomarkers and clinical outcomes of lenvatinib (L) + pembrolizumab (P) in advanced endometrial cancer (EC): Results from KEYNOTE-146/study 111
42. 789P PD-L1 and tumor mutational burden (TMB) in standard-of-care (SOC): Treated advanced cervical cancer
43. 61MO Biomarker analysis of men with enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) + enza in KEYNOTE-199
44. Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab
45. 1442P Association of TMB using the Foundation Medicine Companion Diagnostic (F1CDx) with efficacy of first-line pembrolizumab (pembro) or pembro plus chemotherapy (pembro + chemo) versus chemo in patients with gastric cancer (gc) from KEYNOTE-062
46. 747P Association of TMB with efficacy of pembrolizumab (pembro) in patients (pts) with advanced urothelial cancer (UC): Results from KEYNOTE-045 and KEYNOTE-052
47. Environmental impact assessments can misrepresent species distributions: a case study of koalas in Queensland, Australia.
48. LBA5 - KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC
49. LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042
50. OA04.05 KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.